

Remodeling Innovation

Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in **HCM** & Beyond

Sunday, September 29, 2024

5:00–5:30 PM EDT: Registration & Dinner

5:30–6:30 PM EDT: Symposium

Signia by Hilton Atlanta Georgia World Congress Center
Triumph Ballroom F (Second Floor)
159 Northside Drive NW, Atlanta, GA

**CME/MOC/
AAPA-Certified
Live Activity**




CO-CHAIR & PRESENTER

Milind Desai, MD, MBA, FACC, FAHA, FESC
Cleveland Clinic Lerner College of Medicine
HCM Center
Heart and Vascular Institute
Cleveland Clinic
Cleveland, Ohio



CO-CHAIR & PRESENTER

Anjali Tiku Owens, MD
University of Pennsylvania Perelman
School of Medicine
Philadelphia, Pennsylvania



This Satellite Symposium is presented through a collaboration between PVI, PeerView Institute for Medical Education, and the Heart Failure Society of America. The program topic, learning objectives, and faculty have been reviewed and approved by the ASM Satellite Review Committee. Satellite sessions are not a part of the scientific program as planned and executed by the HFSA Program Committee.

Register online: [PeerView.com/2024HCM-Attend](https://www.peerview.com/2024HCM-Attend)

Key Reasons to Attend

- Strengthen your understanding of the underlying pathophysiology of oHCM, nHCM, and HFpEF and how it relates to the mechanism of action, clinical trial results, and real-world performance of cardiac myosin inhibitors (CMI)
- Improve your ability to identify patients who may benefit from a CMI and utilize shared decision-making skills to build modern, individualized treatment plans



**Pre-Register
Now!**

Agenda

- 5:00 PM EDT: Registration & Dinner
- 5:30 PM EDT: In-Person & Virtual Symposium
 - Welcome and Introduction
 - Research Insights: Clinical Trial Results for Cardiac Myosin Inhibitors
 - Real-World Experience: Meeting Patient Needs With Cardiac Myosin Inhibitors
 - What's Next: New Indications, New Agents
 - Summary and Q&A
- 6:30 PM EDT: Adjourn

Register Today!

Activity Description

Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 1 in 200 people, with a mortality rate about three times greater than that of similar individuals without HCM. In the past, when patients progressed to severe symptomatic obstructive HCM (oHCM), their options were limited to invasive treatments such as septal reduction therapy (SRT) or medications that inconsistently addressed symptoms. In 2022, a first-in-class cardiac myosin inhibitor (CMI) became available that targets the underlying pathophysiology of HCM, alleviating symptoms and improving functional outcomes in patients with oHCM. Notably, phase 3 evidence has demonstrated that a CMI can significantly reduce the need for SRT in patients with severely symptomatic oHCM. CMIs are also potentially disease-modifying, a characteristic relevant to patient populations beyond oHCM. How are these innovations impacting patient care strategies and clinical workflows?

Join PeerView Live and Mended Hearts for a Clinical Consults event that explores the clinical research and real-world evidence for CMIs through the lens of everyday patient care. By the end, learners will have improved their skills and strategies for identifying appropriate patients for CMI therapy and crafting individualized management plans using the principles of shared decision-making. Learners will also be able to better explain the how and why of CMIs and understand their potential in nonobstructive HCM and HFpEF. Register today to start remodeling your clinical practice!

Target Audience

This activity has been designed to meet the educational needs of cardiologists, heart failure specialists, cardiovascular surgeons, cardiology, advanced practice clinicians, and other professionals involved in the management of HCM and related conditions.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Explain the mechanistic rationale for cardiac myosin inhibition and the effects on myosin modulation and myocardial function
- Identify patients who may benefit from treatment with cardiac myosin inhibitors
- Employ shared decision-making to incorporate cardiac myosin inhibitors into treatment regimens for patients with oHCM, including as an alternative to SRT, consistent with the totality of evidence, best practices, and health equity goals
- Appraise study designs, emerging data, and the potential clinical implications of cardiac myosin inhibitors in nHCM and HFpEF



The Mended Hearts, Inc.



Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.